Scholars Central

Case reportPublished 6 Sep 2014

Diabetic Ketoacidosis Secondary to L-Asparaginase and Dexamethasone during Treatment for Acute Lymphoblastic Leukaemia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Diabetic ketoacidosis is an unusual adverse event following chemotherapy for acute lymphoblastic leukaemia. Treatment of haematological malignancies with L-asparaginase has been associated with hyperglycaemia in 1-2% of patients. The concomitant use of glucocorticoids has an additional deleterious effect. We describe a case of diabetic ketoacidosis occurring in a 25 year old male following treatment with L-asparaginase and high dose dexamethasone. Insulin therapy was required only for the duration of treatment. Greater awareness of this adverse effect may reduce the significant morbidity associated with treatment for leukaemia. Background Glucocorticoids are commonly used to treat a variety of illnesses, and are a vital part of many chemotherapy regimens. However, their use is accompanied by side effects including hyperglycaemia. The mechanisms are multifactorial, and include opposition of insulin action, augmentation of hepatic gluconeogenesis and inhibition of glucose uptake in adipose tissue [1,2]. L-asparaginase is an agent used to treat Acute Lymphoblastic Leukaemia (ALL) which is reported to cause hyperglycaemia in approximately 10% of patients [3]. However, this has mostly been described in the paediatric population. We present a case of Diabetic Ketoacidosis (DKA) in a 25 year old patient without previously known diabetes who had leukaemia treated with glucocorticoids and L-asparaginase. Case Presentation We describe a case of a 25 year old Chinese male who was diagnosed with T-cell Acute Lymphoblastic Leukaemia (ALL) in December 2010. Baseline fasting Blood Glucose Level (BGL) was normal at 5.4 mmol/L (97.2 mg/dL). The patient commenced chemotherapy based on the AIEOP-BMF ALL 2009 protocol, consisting of daunorubicin, vincristine, colaspase, cyclophosphamide, intrathecal methotrexate and dexamethasone. As part of the induction phase, he was treated with prednisolone 105 mg (60 mg/m2/day) daily for 28 days. Following this, he received high dose dexamethasone 36 mg (20 mg/m2/day) with each treatment cycle for 3 cycles followed by a re-intensification phase, which included vincristine, doxorubicin, L-asparaginase and dexamethasone 18 mg for 14 days. After commencement of chemotherapy, he had random capillary BGLs performed which ranged between 4.6 to 11.3 mmol/L (82.8 to 203.4 mg/dL). In August 2011, 8 months after the diagnosis of ALL and 2 weeks after commencing L-asparaginase, on a weaning dose of dexamethasone 2 mg twice daily, the patient became acutely unwell with significant polyuria and polydipsia for 3 days prior to admission. He did not have a family history of diabetes mellitus or autoimmunity. On physical examination, he was dehydrated and afebrile. He had no clinical evidence of acute pancreatitis. Laboratory investigations showed a blood glucose level of 41.7 mmol/L (751 mg/dl) and capillary blood ketones 6.0 mmol/L. An arterial blood gas analysis showed a pH 7.24, bicarbonate 11.0 mmol/L, base excess -15.0 mmol/L, anion gap 25 mEq/L and lactate 1.9 mmol/L, confirming the diagnosis of a J Diabetes Metab ISSN: 2155-6156 JDM, an open access journal high anion gap metabolic acidosis consistent with DKA. Due to recent chemotherapy, other parameters were also deranged, with a leukocyte count of 0.8x109/L (3.7-9.5x109/L) including significant neutropaenia, and platelet count of 35x109/L (150-400x109/L). Blood and urine cultures were negative and CRP (C-reactive protein) was normal (<5 mg/L). HbA1c was elevated at 62 mmol/mol (7.7%), reflecting a period of hyperglycaemia prior to presentation. His haemoglobin was normal at 142 g/L (130-180 g/L) having had a blood transfusion 3 months prior to presentation. Islet cell antibodies were not detected. Dexamethasone was ceased, an insulin infusion commenced, and he was discharged on a basal bolus regimen of insulin aspart and glargine. Over the next 4 months, the patient completed re-intensification phase chemotherapy with high dose dexamethasone. His glycaemic control remained stable on insulin with BGLs between 4-10 mmol/L (72-180 mg/dl). In December 2011, maintenance chemotherapy was commenced, consisting of methotrexate and 6-mercaptopurine for the ensuing 15 months. Despite withdrawal of glucocorticoids , the patient continued to require insulin therapy for the next 6 months. In August 2012, 8 months after glucocorticoids were stopped, he ceased insulin therapy. His HbA1c was 4.8% (29 mmol/mol). Twelve months after cessation of insulin, his fasting C-peptide was in the upper normal range at 0.59 nmol/L. Anti-GAD antibodies was negative. A 75 gram oral glucose tolerance test was normal with fasting glucose of 4.6 mmol/L (83 mg/dl), and 2 hour glucose of 5.3 mmol/L (95 mg/dL). To date, the patient remains euglycaemic and in remission from leukaemia.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectDiabetes & Endocrinology
  • SubjectHaematology
  • SubjectOncology & Cancer